High-resolution crystal structure of human protease-activated receptor 1

Nature

Volumn 492, Issue 7429, 2012, Pages 387-392

  Zhang, Cheng ^a   Srinivasan, Yoga ^b   Arlow, Daniel H ^c   Fung, Juan Jose ^a,e   Palmer, Daniel ^b   Zheng, Yaowu ^b,f   Green, Hillary F ^c   Pandey, Anjali ^d   Dror, Ron O ^c   Shaw, David E ^c   Weis, William I ^a   Coughlin, Shaun R ^b   Kobilka, Brian K ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c D E SHAW RESEARCH   (United States)

^d Portola Pharmaceuticals   (United States)

^e ProNovus Bioscience   (United States)

^f NORTHEAST NORMAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; PROTEINASE ACTIVATED RECEPTOR 1; VORAPAXAR;

CRYSTAL STRUCTURE; ENZYME ACTIVITY; INHIBITION; LIGAND; MOLECULAR ANALYSIS; PEPTIDE; PROTEIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; HUMAN; HYDROGEN BOND; LIGAND BINDING; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN STRUCTURE;

AMINO ACID MOTIFS; BINDING SITES; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; ENZYME ACTIVATION; HUMANS; HYDROLYSIS; LACTONES; LIGANDS; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; MYOCARDIAL INFARCTION; PROTEIN CONFORMATION; PYRIDINES; RECEPTOR, PAR-1; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, THROMBIN;

EID: 84871411930     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature11701     Document Type: Article

References (70)

1. Vu, T. K., Hung, D. T., Wheaton, V. I. & Coughlin, S. R. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64, 1057-1068 (1991).
2. Coughlin, S. R. Thrombin signalling and protease-activated receptors. Nature 407, 258-264 (2000).
3. Vu, T. K., Wheaton, V. I., Hung, D. T., Charo, I. & Coughlin, S. R. Domains specifying thrombin-receptor interaction. Nature 353, 674-677 (1991).
4. Chen, J., Ishii, M., Wang, L., Ishii, K. & Coughlin, S. R. Thrombin receptor activation. Confirmation of the intramolecular tethered liganding hypothesis and discovery of an alternative intermolecular liganding mode. J. Biol. Chem. 269, 16041-16045 (1994).
5. Liu, L. W., Vu, T. K., Esmon, C. T. & Coughlin, S. R. The region of the thrombin receptor resembling hirudin binds to thrombin and alters enzyme specificity. J. Biol. Chem. 266, 16977-16980 (1991).
6. Ishii, K., Hein, L., Kobilka, B. & Coughlin, S. R. Kinetics of thrombin receptor cleavage on intact cells. Relation to signaling. J. Biol. Chem. 268, 9780-9786 (1993).
7. Mathews, I. I. et al. Crystallographic structures of thrombin complexed with thrombin receptor peptides: existence of expected and novel binding modes. Biochemistry 33, 3266-3279 (1994).
8. Gerszten, R. E. et al. Specificity of the thrombin receptor for agonist peptide is defined by its extracellular surface. Nature 368, 648-651 (1994).
9. Coughlin, S. R. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J. Thromb. Haemost. 3, 1800-1814 (2005).
10. García-López, M. T., Gutierrez-Rodriguez, M. & Herranz, R. Thrombin-activated receptors: promising targets for cancer therapy? Curr. Med. Chem. 17, 109-128 (2010).
11. Ramachandran, R., Noorbakhsh, F., Defea, K. & Hollenberg, M. D. Targeting proteinase-activated receptors: therapeutic potential and challenges. Nature Rev. Drug Discov. 11, 69-86 (2012).
12. Ishii, K. et al. Determinants of thrombin receptor cleavage. Receptor domains involved, specificity, and role of the P3 aspartate. J. Biol. Chem. 270, 16435-16440 (1995).
13. Shapiro, M. J., Trejo, J., Zeng, D. & Coughlin, S. R. Role of the thrombin receptor's cytoplasmic tail in intracellular trafficking. Distinct determinants for agonisttriggered versus tonic internalization and intracellular localization. J. Biol. Chem. 271, 32874-32880 (1996).
14. Trejo, J. & Coughlin, S. R. The cytoplasmic tails of protease-activated receptor-1 and substance P receptor specify sorting to lysosomes versus recycling. J. Biol. Chem. 274, 2216-2224 (1999).
15. Trejo, J., Hammes, S. R. & Coughlin, S. R. Termination of signaling by proteaseactivated receptor-1 is linked to lysosomal sorting. Proc. Natl Acad. Sci. USA 95, 13698-13702 (1998).
16. Shapiro, M. J. & Coughlin, S. R. Separate signals for agonist-independent and agonist-triggered trafficking of protease-activated receptor 1. J. Biol. Chem. 273, 29009-29014 (1998).
17. Hein, L., Ishii, K., Coughlin, S. R. & Kobilka, B. K. Intracellular targeting and trafficking of thrombin receptors. A novel mechanism for resensitization of a G protein-coupled receptor. J. Biol. Chem. 269, 27719-27726 (1994).
18. Chackalamannil, S. et al. Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents. J. Med. Chem. 48, 5884-5887 (2005).
19. Morrow, D. A. et al. Vorapaxar in the secondary prevention of atherothrombotic events. N. Engl. J. Med. 366, 1404-1413 (2012).
20. Kosoglou, T. et al. Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects. Eur. J. Clin. Pharmacol. 68, 249-258 (2012).
21. Soto, A. G. & Trejo, J. N-linked glycosylation of protease-activated receptor-1 second extracellular loop: a critical determinant for ligand-induced receptor activation and internalization. J. Biol. Chem. 285, 18781-18793 (2010).
22. Wu, B. et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330, 1066-1071 (2010).
23. Manglik, A. et al. Crystal structure of the micro-opioid receptor bound to a morphinan antagonist. Nature 485, 321-326 (2012).
24. Wu, H. et al. Structure of the human k-opioid receptor in complex with JDTic. Nature 485, 327-332 (2012).
25. Granier, S. et al. Structure of the d-opioid receptor bound to naltrindole. Nature 485, 400-404 (2012).
26. Smit, M. J. et al. Pharmacogenomic and structural analysis of constitutive g protein-coupled receptor activity. Annu. Rev. Pharmacol. Toxicol. 47, 53-87 (2007).
27. Schwartz, T. W., Frimurer, T. M., Holst, B., Rosenkilde, M. M. & Elling, C. E. Molecular mechanism of 7TM receptor activation-a global toggle switch model. Annu. Rev. Pharmacol. Toxicol. 46, 481-519 (2006).
28. Fredriksson, R., Lagerstrom, M. C., Lundin, L. G. & Schioth, H. B. The G-proteincoupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol. Pharmacol. 63, 1256-1272 (2003).
29. Rasmussen, S. G. et al. Structure of a nanobody-stabilized active state of the b2 adrenoceptor. Nature 469, 175-180 (2011).
30. Rosenbaum, D. M. et al. Structure and function of an irreversible agonist-b2 adrenoceptor complex. Nature 469, 236-240 (2011).
31. Rasmussen, S. G. et al. Crystal structure of the b2 adrenergic receptor-Gs protein complex. Nature 477, 549-555 (2011).
32. Harding, M. M. Metal-ligand geometry relevant to proteins and in proteins: sodium and potassium. Acta Crystallogr. D 58, 872-874 (2002).
33. Horstman, D. A. et al. An aspartate conserved among G-protein receptors confers allosteric regulation of a2-adrenergic receptors by sodium. J. Biol. Chem. 265, 21590-21595 (1990).
34. Costa, T., Lang, J., Gless, C. & Herz, A. Spontaneous association between opioid receptors and GTP-binding regulatory proteins in native membranes: specific regulation by antagonists and sodium ions. Mol. Pharmacol. 37, 383-394 (1990).
35. Gao, Z. G. & Ijzerman, A. P. Allosteric modulation of A2A adenosine receptors by amiloride analogues and sodium ions. Biochem. Pharmacol. 60, 669-676 (2000).
36. Selent, J., Sanz, F., Pastor, M. & De Fabritiis, G. Induced effects of sodium ions on dopaminergic G-protein coupled receptors. PLOS Comput. Biol. 6, e1000884 (2010).
37. Wilson, M. H., Highfield, H. A. & Limbird, L. E. The role of a conserved intertransmembrane domain interface in regulating a2a-adrenergic receptor conformational stability and cell-surface turnover. Mol. Pharmacol. 59, 929-938 (2001).
38. Neve, K. A. et al. Modeling and mutational analysis of a putative sodium-binding pocket on the dopamine D2 receptor. Mol. Pharmacol. 60, 373-381 (2001).
39. Palczewski, K. et al. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 289, 739-745 (2000).
40. Hanson, M. A. et al. Crystal structure of a lipid G protein-coupled receptor. Science 335, 851-855 (2012).
41. Lerner, D. J., Chen, M., Tram, T. & Coughlin, S. R. Agonist recognition by proteinaseactivated receptor 2 and thrombin receptor. Importance of extracellular loop interactions for receptor function. J. Biol. Chem. 271, 13943-13947 (1996).
42. Nanevicz, T. et al. Mechanisms of thrombin receptor agonist specificity. Chimeric receptors and complementary mutations identify an agonist recognition site. J. Biol. Chem. 270, 21619-21625 (1995).
43. Blackhart, B. D. et al. Extracellular mutations of protease-activated receptor-1 result in differential activation by thrombin and thrombin receptor agonist peptide. Mol. Pharmacol. 58, 1178-1187 (2000).
44. Seeley, S. et al. Structural basis for thrombin activation of a protease-activated receptor: inhibition of intramolecular liganding. Chem. Biol. 10, 1033-1041 (2003).
45. Bahou, W. F., Kutok, J. L., Wong, A., Potter, C. L. & Coller, B. S. Identification of a novel thrombin receptor sequence required for activation-dependent responses. Blood 84, 4195-4202 (1994).
46. Nanevicz, T., Wang, L., Chen, M., Ishii, M. & Coughlin, S. R. Thrombin receptor activating mutations. Alteration of an extracellular agonist recognition domain causes constitutive signaling. J. Biol. Chem. 271, 702-706 (1996).
47. Shaw, D. E. et al. Millisecond-scalemolecular dynamics simulations onAnton. Proc. Conf. High Performance Computing Networking, Storage Analysis Article no. 39 (2009).
48. Rosenbaum, D. M. et al. GPCR engineering yields high-resolution structural insights into b2-adrenergic receptor function. Science 318, 1266-1273 (2007).
49. Caffrey, M. & Cherezov, V. Crystallizing membrane proteins using lipidic mesophases. Nature Protocols 4, 706-731 (2009).
50. Caffrey, M. Crystallizing membrane proteins for structure determination: use of lipidic mesophases. Annu. Rev. Biophys. 38, 29-51 (2009).
51. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1997).
52. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
53. Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D 66, 213-221 (2010).
54. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D. 60, 2126-2132 (2004).
55. Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D 66, 12-21 (2010).
56. The. PyMOL Molecular Graphics System v. 1. 5. 0. 4 (Schrödinger, LLC, 2010).
57. Cornelissen, I. et al. Roles and interactions among protease-activated receptors and P2ry12 in hemostasis and thrombosis. Proc. Natl Acad. Sci. USA 107, 18605-18610 (2010).
58. Dror, R. O. et al. Identification of two distinct inactive conformations of the b2-adrenergic receptor reconciles structural and biochemical observations. Proc. Natl Acad. Sci. USA 106, 4689-4694 (2009).
59. Fahmy, K. et al. Protonation states of membrane-embedded carboxylic acid groups in rhodopsin and metarhodopsin II: a Fourier-transform infrared spectroscopy study of site-directed mutants. Proc. Natl Acad. Sci. USA 90, 10206-10210 (1993).
60. Kräutler, V., Gunsteren, W. F. v. & Hünenberger, P. H. A fast SHAKE algorithm to solve distance constraint equations for small molecules in molecular dynamics simulations. J. Comput. Chem. 22, 501-508 (2001).
61. Tuckerman, M., Berne, B. J. & Martyna, G. J. Reversible multiple time scale molecular dynamics. J. Chem. Phys. 97, 1990-2001 (1992).
62. Shan, Y., Klepeis, J. L., Eastwood, M. P., Dror, R. O. & Shaw, D. E. Gaussian split Ewald: A fast Ewald mesh method for molecular simulation. J. Chem. Phys. 122, 54101 (2005).
63. Dror, R. O. et al. Activation mechanism of the b2-adrenergic receptor. Proc. Natl Acad. Sci. USA 108, 18684-18689 (2011).
64. Dror, R. O. et al. Pathway and mechanism of drug binding to G-protein-coupled receptors. Proc. Natl Acad. Sci. USA 108, 13118-13123 (2011).
65. MacKerell, A. D. Jr, Bashford, D. & Bellott, M. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J. Phys. Chem. B 102, 3586-3616 (1998).
66. Mackerell, A. D. Jr, Feig, M. & Brooks, C. L. III. Extending the treatment of backbone energetics in protein force fields: limitations of gas-phase quantummechanics in reproducing protein conformational distributions in molecular dynamics simulations. J. Comput. Chem. 25, 1400-1415 (2004).
67. Piana, S., Lindorff-Larsen, K. & Shaw, D. E. How robust are protein folding simulations with respect to force field parameterization? Biophys. J. 100, L47-L49 (2011).
68. Klauda, J. B. et al. Update of the CHARMM all-atom additive force field for lipids: validation on six lipid types. J. Phys. Chem. B 114, 7830-7843 (2010).
69. Vanommeslaeghe, K. et al. CHARMM general force field: a force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. J. Comput. Chem. 31, 671-690 (2010).
70. Humphrey, W., Dalke, A. & Schulten, K. VMD: visual molecular dynamics. J. Mol. Graph. 14, 33-38 (1996).